Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 9Phase 2/3 3Phase 1 2Phase 1/2 1

Status

Recruiting 2Completed 1

Sponsor Class

NIH 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1

Interventions

Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiotherapy 8Doxorubicin 8Nivolumab 7Immunoglobulin G 6Disulfides 6Cisplatin 6Biopsy 6Radiation 5Platinum 5Paclitaxel 5Cytarabine 5Bevacizumab 51,2-diaminocyclohexaneplatinum II citrate 5atezolizumab 4Vincristine 4Taxes 4Prednisone 4Methotrexate 4Daunorubicin 4Cyclophosphamide 4Cetuximab 4Carboplatin 4prednylidene 3merphos 3liposomal doxorubicin 3deltacortene 3Temozolomide 3Radiotherapy, Intensity-Modulated 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × NIH × merphos × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT05691478 2026-06-03

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

National Cancer Institute (NCI)

Phase 2/3 Recruiting
1,122 enrolled
Sarcoma

Osteosarcoma

NCT00720109 2020-04-13

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2/3 Completed
63 enrolled 13 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡